Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of Wisconsin, Madison
Collaborators
NCT06974734 · Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, and more
NCT03128008 · Carcinoma, Non Small Cell Lung (NSCLC)
NCT00553254 · Carcinoma, Non Small Cell Lung
NCT01671332 · Carcinoma, Non Small Cell Lung
NCT01469000 · Carcinoma, Non Small Cell Lung
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions